Matches in UGent Biblio for { <https://biblio.ugent.be/publication/145682#aggregation> ?p ?o. }
Showing items 1 to 33 of
33
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B101521.
- aggregation creator B101522.
- aggregation creator B101523.
- aggregation creator B101524.
- aggregation creator B101525.
- aggregation creator person.
- aggregation date "2001".
- aggregation hasFormat 145682.bibtex.
- aggregation hasFormat 145682.csv.
- aggregation hasFormat 145682.dc.
- aggregation hasFormat 145682.didl.
- aggregation hasFormat 145682.doc.
- aggregation hasFormat 145682.json.
- aggregation hasFormat 145682.mets.
- aggregation hasFormat 145682.mods.
- aggregation hasFormat 145682.rdf.
- aggregation hasFormat 145682.ris.
- aggregation hasFormat 145682.txt.
- aggregation hasFormat 145682.xls.
- aggregation hasFormat 145682.yaml.
- aggregation isPartOf urn:issn:0732-183X.
- aggregation language "eng".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials".
- aggregation abstract "Purpose: The logic behind the application of luteinizing hormone-releasing hormone (LHRH) agonists in combination with tamoxifen in premenopausal women is that LHRH agonists on the one hand suppress the tamoxifen-induced stimulation of the pituitary-ovarian function and, on the other hand, seem as effective as surgical castration. This meta-analysis combines all randomized evidence to compare the combined treatment with LHRH agonist alone with respect to overall survival, progression-free survival, and objective response in premenopausal women with advanced breast cancer. Patients and Methods: Four clinical trials randomising a total of 506 premenopausal women with advanced breast cancer to LHRH agonist alone or to the combined treatment of LHRH agonist plus tamoxifen were identified. Meta-analytic techniques were used to analyze individual patient data from these trials. Results: With a median follow-vp of 6.8 years, there was a significant survival benefit (stratified log-rank test, P =.02; hazards ratio [HR] = 0.78) and progression-free survival benefit (stratified log-rank test, P =.0003; HR = 0.70) in favor of the combined treatment. The overall response rate was significantly higher on combined endocrine treatment (stratified Mantel Haenszel test, P =.03; odds ratio = 0.67). Conclusion: The combination of LHRH agonist plus tamoxifen is superior to LHRH agonist alone in premenopausal women with advanced breast cancer. Therefore, if a premenopausal woman with advanced breast cancer is thought to be suitable for endocrine treatment it is proposed that the combination of a LHRH agonist plus tamoxifen be considered as the new standard treatment. J Clin Oncol 19:343-353. (C) 2001 by American Society of Clinical Oncology.".
- aggregation authorList BK260676.
- aggregation endPage "353".
- aggregation issue "2".
- aggregation startPage "343".
- aggregation volume "19".
- aggregation isDescribedBy 145682.
- aggregation similarTo LU-145682.